The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
Rentschler Biopharma launched an expanded service offering at its dedicated Advanced Therapy Medicinal Products (ATMP) site in Stevenage, U.K. The company introduced a new lentiviral vector ...
As gene and cell therapies mature, developers are increasingly looking beyond existing delivery systems to address challenges around targeting, immunogenicity, manufacturability, and cost. Dr. Angelo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results